Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02480270 · ClinicalTrials.gov registry record

Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation

A clinical trial, sponsored by University of Colorado, Denver.

Completed
Registry status
32
Enrollment target

NCT02480270 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02480270 has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
32 participants
Enrollment target

Study Summary

This study plans to learn more about the effect of oral antibiotics for an outpatient pulmonary exacerbation (respiratory illness) on sputum (mucus) bacterial infections, lung function, airway inflammation and quality of life. In this study subjects will perform pulmonary function tests, provide a sputum sample and complete a questionnaire at two separate clinic visits. If a subject is unable to cough up sputum in clinic he or she will be asked to breathe in a salt water solution to help cough up sputum. The first sputum sample will be obtained at the first visit (within 48 hours of starting antibiotics). Pulmonary function testing and the questionnaire will also be completed at this time. Subjects will complete a two week course of oral antibiotics at home. During these two weeks subjects will be asked to write down the times antibiotics are taken and airway clearance (vest treatment) is performed. Within one week of completing the antibiotic course subjects will return to clinic for a second visit. At that time a sputum sample will be obtained again and if subjects are unable to cough up sputum they will again be asked to breathe in salt water solution to help cough up sputum. Pulmonary function testing and the questionnaire will also be completed at this second visit. Sputum samples will be tested for infections with bacteria and viruses. Sputum samples will also be used to measure markers of airway inflammation (swelling). The investigators hypothesize that the use of two weeks of oral antibiotics for the treatment of a pulmonary exacerbation will result in a decrease in the amount of bacteria measured in sputum. Additionally the investigators hypothesize that treatment with antibiotics will lead to an improvement in lung function, a decrease in airway inflammation and an improvement in quality of life measurements.

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2014-08
Est. Completion 2017-01-04

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT02480270

The ClinicalTrials.gov registry entry for NCT02480270 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02480270 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02480270 about?

NCT02480270 is a clinical study titled "Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation". This study plans to learn more about the effect of oral antibiotics for an outpatient pulmonary exacerbation (respiratory illness) on sputum (mucus) bacterial infections, lung function, airway inflammation and quality of life. In this study subjects will perform pulmonary function tests, provide a s...

What is the current status of trial NCT02480270?

This trial is currently completed. The enrollment target is 32 participants. The study started on 2014-08. Estimated completion is 2017-01-04.

Who is sponsoring clinical trial NCT02480270?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.